Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript

Company Overview - Summit Therapeutics focuses primarily on its main pipeline asset, ivonescimab, which is a key component of its strategic direction [2] - The company entered into a strategic partnership with Akeso Bio in December 2022, which became effective in January 2023, granting Summit rights to ivonescimab in major markets including North America, South America, Europe, Africa, the Middle East, and Japan, excluding China and Korea [2] Clinical Development - The strategic partnership aims to expedite late-stage clinical studies for ivonescimab, driven by encouraging data from Phase II trials [3]